Ranolazine用於治療穩定型心絞痛之療效- Salazar | 合法藥品大搜索

2017年2月8日—Toassesstheeffectsofranolazineoncardiovascularandnon‐cardiovascularmortality,all‐causemortality,qualityoflife,acutemyocardial ...

The main results are summarised in analyses for ranolazine as monotherapy compared to placebo (Analysis 1.2[1]; Analysis 1.3[2]; Analysis 1.4[3]; Analysis 1.5[4]; Analysis 2.1[5]; Analysis 2.2[6]) and as add‐on therapy compared to placebo (Analysis 3.1[7]; Analysis 3.2[8]; Analysis 3.3[9]; Analysis 3.4[10]; Analysis 3.5[11]; Analysis 4.1[12]; Analysis 4.2[13]).

Data were reported for ranolazine as monotherapy compared to placebo for quality of life (Tagliamonte 2015[14]) and frequency of angina episodes (RAN080 2005[15]; Thadani 1994[16]). These data could not be pooled in a meta‐analysis due to incompleteness.

Ranolazine was compared to other first‐ (RAN080 2005[17], atenolol 100 mg once daily) and second‐line anti‐anginals (Sandhiya 2015[18]; Villano 2013[19]; trimetazidine 35 mg twice daily and ivabradine 5 mg twice daily respectively), either as monotherapy (RAN080 2005[20]; Sandhiya 2015[21]) or add‐on therapy (Villano 2013[22]). Data could not be...